Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thromboembolism 1Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 6Cisplatin 5Radiotherapy 4Paclitaxel 3Nivolumab 3lenvatinib 2Specimen Handling 2Platinum 2Papillomavirus Vaccines 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Gemcitabine 2Carboplatin 2CTLA-4 Antigen 2Bleomycin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1rocakinogene sifuplasmid 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cemiplimab 1belzutifan 1antineoplaston AS 2-1 1antineoplaston A10 1alovudine 1aldesleukin 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vulvar Neoplasms × Fondaparinux × Clear all
NCT00381888 2017-12-28

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
44 enrolled 7 charts
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Thromboembolism, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡